Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer

Malin Dahlgren (1), MSc,1,2 Anthony M. George (3), MSc,1,2 Christian Brueffer (4), PhD,1,2 Sergii Gladchuk (5), MSc,1,2 Yilun Chen, MSc,1,2 Johan Vallon-Christersson (6), PhD,1,2 Cecilia Hegardt, PhD,1,2 Jari Häkkinen, PhD,1,2 Lisa Rydén, MD, PhD,3 Martin Malmberg (4), MD, PhD,4 Christer Larsson, PhD,5 Sofia K. Gruvberger-Saal (6), PhD,1,6 Anna Ehinger (6), MD, PhD,7 Niklas Loman, MD, PhD,4 Åke Borg, PhD,1,2 Lao H. Saal (6), MD, PhD1,2,*

1Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 2Lund University Cancer Center, Medicon Village, Lund, Sweden, 3Department of Surgery, Skåne University Hospital, Lund, Sweden, 4Department of Oncology, Skåne University Hospital, Lund, Sweden, 5Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden, 6Current affiliation: Center for Molecular Diagnostics, Skåne University Hospital, Lund, Sweden and 7Department of Pathology, Skåne University Hospital, Lund, Sweden

Correspondence to: Lao H. Saal, MD, PhD, Division of Oncology, Department of Clinical Sciences Lund, Lund University Cancer Center, Medicon Village 404-B2, Lund University, SE-22381 Lund, Sweden (e-mail: lao.saal@med.lu.se).

Table 1, available online] that have been experimentally verified

Abstract

Background: More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene ESR1), the most important factor for directing anti-estrogenic endocrine therapy (ET). Recently, mutations in ESR1 were identified as acquired mechanisms of resistance to ET, found in 12% to 55% of metastatic breast cancers treated previously with ET. Methods: We analyzed 3217 population-based invasive primary (nonmetastatic) breast cancers (within the SCAN-B study, ClinicalTrials.gov NCT02306096), sampled from initial diagnosis prior to any treatment, for the presence of ESR1 mutations using RNA sequencing. Mutations were verified by droplet digital polymerase chain reaction on tumor and normal DNA. Patient outcomes were analyzed using Kaplan-Meier estimation and a series of 2-factor Cox regression multivariable analyses. Results: We identified ESR1 resistance mutations in 30 tumors (0.9%), of which 29 were ER positive (1.1%). In ET-treated disease, presence of ESR1 mutation was associated with poor relapse-free survival and overall survival (2-sided log-rank test $P < .001$ and $P = .008$, respectively), with hazard ratios of 3.00 (95% confidence interval = 1.56 to 5.88) and 2.51 (95% confidence interval = 1.24 to 5.07), respectively, which remained statistically significant when adjusted for other prognostic factors. Conclusions: These population-based results indicate that ESR1 mutations at diagnosis of primary breast cancer occur in about 1% of women and identify for the first time in the adjuvant setting that such preexisting mutations are associated to eventual resistance to standard hormone therapy. If replicated, tumor ESR1 screening should be considered in ER-positive primary breast cancer, and for patients with mutated disease, ER degraders such as fulvestrant or other therapeutic options may be considered as more appropriate.

The estrogen receptor alpha (ER; encoded by the ESR1 gene) has been known for decades as a targetable driver of breast tumor growth. Standard of care for ER-positive breast cancer includes endocrine therapy (ET), for example, treatment with estrogen receptor modulators such tamoxifen, aromatase inhibitors such as letrozole in the adjuvant and advanced settings, and ER degraders such as fulvestrant in the advanced setting. Recently, recurrent mutations in ESR1 were identified in 12% to 55% of metastatic breast cancers, enriched among patients who had previously received ET (1-4). In these studies, a series of mutations were described, most of them located in the ligand-binding domain of the estrogen receptor, with the main hotspot among the amino acid residues 536-538 (3). Mutations in this site allow stabilization of the receptor in the more active, agonist conformation, leading to increased downstream transcription of ER targets. The endocrine-resistance mutations include at least 13 variants [reviewed in (5), also see Supplementary Table 1, available online] that have been experimentally verified to confer increased activity in the absence of estrogenic ligands, some of which have been associated to resistance to ET (1-4,6).

Depending on the amino acid substitution, functionally active ligand-binding domain mutations have also been shown to

Received: 21 October 2020; Revised: 29 January 2021; Accepted: 26 March 2021

© The Author(s) 2021. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
increase tumor cell growth and migration in monolayer cell culture (3,4,7) and xenograft growth in mouse models (1). Among the most commonly affected sites is amino acid Y537 with substitutions of S, C, D, or N along with D538G, all giving rise to increased ER activity (7,8). Although apparently similar with regard to mechanism, in vitro experiments show differing potency to confer ligand-independent and modulator-resistant growth, with Y537S being the most potent and others such as E380Q more moderate in its effects (8). Additionally, recent studies have revealed that different variants also give rise to distinct transcriptional phenotypes (9,10).

In contrast to the high rate of ESR1 mutation in advanced breast cancer (3,4,6,11), the prevalence of resistance mutations in primary breast tumors has been reportedly very low, ranging from 0% to 7% in published studies (3,4,12-14). In cases of ESR1 mutation-positive metastatic disease, the matched primary tumors when tested have been predominantly mutation negative, suggesting that many of these mutations are selected for under therapeutic pressure and during tumor progression (5,14).

In this study, we aimed to expand on the understanding of the ER-activating ESR1 resistance mutations in primary breast cancer and investigate the relationship of preexisting ESR1 mutations to ET resistance across a very large, real-world population-based early breast cancer cohort. The SCAN-B initiative (ClinicalTrials.gov NCT02306096) (15-17), initiated in 2010, is the largest prospective population-based collection of breast tumor samples undergoing routine RNA sequencing (RNA-seq); all newly diagnosed breast cancer patients in the participating 9 hospitals are offered enrollment. In the present study—the largest to our knowledge—we have analyzed the tumor samples within days of surgery (15,16). RNA and DNA are isolated from tumor specimens using Qiagen AllPrep method (15,16). The 3217-patient SCAN-B series studied herein corresponds to an updated version of the patient group previously described by Brueffer et al. (17). Clinical parameters were determined as per the Swedish standard clinical routine, with greater than 10% positive cells by immunohistochemistry (IHC) scored as hormone receptor positive. Ki67 IHC status was established using local cutoffs (Swedish breast cancer quality assurance guidelines recommend that each laboratory calibrate a cutoff yearly such that one-third of 100 consecutive cases are Ki67 high). Grading was performed according to the Nottingham grading system (18) and pathological staging according to the TNM classification of malignant tumors (American Joint Committee on Cancer, 7th ed.). Updated clinical data and follow-up was retrieved from the Swedish National Quality Register.

## Methods

### SCAN-B Cohort and RNA Sequencing

The study was approved by the Regional Ethical Review Board of Lund (diary numbers 2007/155, 2009/658, 2010/383, 2012/58, 2013/459) and the Swedish Data Inspection group (364-2010). Written informed consent is obtained from all study participants. The SCAN-B study is a multicenter prospective study that has enrolled more than 16 000 primary breast cancer patients to date and performs RNA sequencing on the tumor samples within days of surgery (15,16). RNA and DNA are isolated from tumor specimens using Qiagen AllPrep method (15,16). The 3217-patient SCAN-B series studied herein corresponds to an updated version of the patient group previously described by Brueffer et al. (17).

Clinical parameters were determined as per the Swedish standard clinical routine, with greater than 10% positive cells by immunohistochemistry (IHC) scored as hormone receptor positive. Ki67 IHC status was established using local cutoffs (Swedish breast cancer quality assurance guidelines recommend that each laboratory calibrate a cutoff yearly such that one-third of 100 consecutive cases are Ki67 high). Grading was performed according to the Nottingham grading system (18) and pathological staging according to the TNM classification of malignant tumors (American Joint Committee on Cancer, 7th ed.). Updated clinical data and follow-up was retrieved from the Swedish National Quality Register.

### Mutations in RNA-Sequencing Data

For detailed protocols of RNA-sequencing data processing, including variant calling annotation, and filtering, see accompanying Supplementary Methods (available online) and Brueffer et al. (19). In brief, raw RNA-seq reads were trimmed and filtered as previously described (17). Reads were further processed using a modified version of the bcbbio-nextgen 1.0.2 variant pipeline, aligned to the GRCh38.p8 reference genome using HISAT2 2.0.5, and duplicates marked using SAMBLASTER 0.1.24. Variants were called using VarDict-Java 1.5.0 requiring a minimum variant allele fraction of 2.0%. To eliminate germline calls and artifacts resulting from sources such as library preparation and RNA editing, the variants were annotated and filtered using a variety of data sources (Supplementary Methods, available online). Finally, filtered but likely true variant calls were rescued using databases such as the Catalogue of Somatic Mutations in Cancer. The resulting list of mutations was then searched for any of the 13 ESR1 ET resistance mutations previously reported in the literature (Supplementary Table 1, available online).

### Droplet Digital PCR

IBSAFE assays were designed for 5 of the most recurrent ESR1 variants: E380Q, D538G, Y537S, Y537N, and Y537C (SAGAsafe; SAGA Diagnostics AB, Lund, Sweden). Assays were validated using fragmented human male normal DNA (Thermo Fisher Scientific Inc, Waltham, MA, USA) as a negative control and gBlock synthetic DNA sequences (Integrated DNA Technologies BVBA, Leuven, Belgium), containing the respective mutant alleles spiked into wild-type DNA, as positive controls. IBSAFE droplet digital polymerase chain reaction (ddPCR) was performed as previously described (20). For validation of variants found by RNA-seq, 10ng of genomic tumor DNA or germline DNA isolated from whole blood was used.

### Statistical Analyses

Data analysis, data visualization, and statistics were performed using R version 3.6.2 (2019-12-12) with relevant packages (see the Supplementary Methods, available online). For 2-group comparisons, Fisher exact test and Mann-Whitney U test were used. Overall survival (OS) events were defined as death from any cause and relapse-free survival (RFS) events as death from any cause or recurrence of breast cancer (locoregional or distant). P values for survival were calculated using the log-rank test. A series of 2-factor Cox regression multivariable analyses were performed adjusting for the following clinical variables: age at diagnosis (50 years and older or younger than 50 years old), tumor size (>20 or <20 mm), lymph node status, tumor grade, and tumor pathological stage. The proportional hazards assumption was tested using Schoenfeld residuals. Absolute risk for outcome was calculated using the number of events divided by the number of patients with follow-up data in the given group. All tests were 2-sided, and P values of <0.05 or less were considered statistically significant.

### Results

#### Clinical Characteristics

The population-based cohort of 3217 primary breast tumors was RNA sequenced within the framework of the SCAN-B study.
The clinical characteristics of the cohort represent the expected distribution for early breast cancer in Sweden (Table 1): the median patient age at diagnosis was 64 years; 84.6% were ER positive; 71.7% progesterone receptor (PR) positive; 12.9% had HER2 amplification; 35.5% were positive for tumor spread to at least 1 lymph node at the time of surgery; 15.0% were Nottingham histological grade 1, 46.9% grade 2, and 36.1% grade 3. RNA-seq–based gene expression data was also used to determine the PAM50 molecular subtypes of the tumors: 48.0% were classified to the luminal A group, 28.7% HER2-enriched, 9.9% basal-like, and 3.5% normal-like tumors. Postoperative endocrine treatment had been administered to 77.7% of the patients in the cohort, corresponding to 90.5% of the ER-positive subgroup. ET was given as sole adjuvant therapy to 1,579 patients, whereas 914 patients also received chemotherapy. The median follow-up time after diagnosis was 6.29 years.

**Identification of Resistance Mutations**

We searched available resources and literature to identify the ESR1 mutations that have been previously shown to confer resistance to ET and identified 13 functionally validated mutations (Supplementary Table 1, available online). Mutation calling and annotation of the SCAN-B RNA-seq data identified 30 samples with an ESR1 mutation known to cause endocrine resistance, corresponding to 0.9% of all tumors or 1.1% of the ER-positive tumors. The mutations that we identified included 10 tumors with E380Q, 5 with D538G, 5 with S463P, 4 with Y537S, 3 with Y537C, and 1 each of Y537N, L536H, L536P, and L536R at mutant allele fractions (MAFs) varying from 2.0% to 100% (Figure 1). One tumor harbored 2 resistance mutations, D538G and Y537S, at MAFs of 2.1% and 12.5%, respectively.

The ESR1 ET resistance mutation group was similar to the patients with wild-type tumors in the ER-positive and ET-treated cohorts with respect to clinical factors and PAM50 molecular subtypes (Table 1). Patients with ESR1 resistance mutations had a median age of diagnosis of 64.5 years vs 64 years for ESR1 wild-type cases in both the full cohort, the ER-positive cohort, and the group receiving ET (Mann-Whitney U test, P = .046, P = .049, and P = .12, respectively; Table 1). Notably, 100% of the patients in the mutant group were 50 years or older, compared with 81% to 82% in wild-type groups (Mann-Whitney U test, P = .004, P = .006, and P = .01, respectively; Table 1). Of the 30 mutant cases, 29 were ER and/or PR positive, 3 of which were also HER2 amplified; 1 case was ER and PR negative and HER2 amplified, and no mutant cases were triple negative. The percentage of ER positive cells determined by IHC was available for 22 of the ESR1-mutated tumors and ranged from 0% to 100% with a mean of 90.9%. Notably, none of the mutant tumors had been exposed to neoadjuvant endocrine therapy prior to the removal of the surgical specimens used for mutation screening. Postoperative, 27 of the patients were given adjuvant treatment with tamoxifen or aromatase inhibitor, 16 of which received only ET, and 11 of which received chemotherapy in combination with ET; 2 patients received no systemic adjuvant therapy (Table 1).

Detailed clinical parameters and therapies for the patients with ESR1 mutations are provided in Supplementary Table 2 (available online).

**Validation of Variants**

To validate the RNA-seq results using an orthogonal method, we used IBSAFE ddPCR mutation detection assays for the most recurrent amino acids affected (residues 380, 537, and 538) and retrieved tumor and blood DNA from the biobank for those samples that were available. In 100% (18 of 18), the mutations were validated in tumor DNA, and in 100% (11 of 11) with matching germline DNA from blood, the mutations were confirmed as somatic (Supplementary Table 3, available online). In tumor DNA, the MAFs varied from 5.2% to 70.0% and generally reflected the frequencies determined from RNA sequencing (Figure 1, C).

**ESR1 Mutation and Patient Outcome**

Based on evidence from metastatic breast cancer, we hypothesized that early-stage breast cancers with preexisting ET-resistance ESR1 mutations would be poor responders to standard endocrine therapies. To test this, we evaluated patient survival using Kaplan-Meier analyses and log-rank tests of patients with or without 1 of the mutations of interest. Included in the ET group (n = 2,499) were all patients that had undergone any type of adjuvant hormonal therapy. Of these patients, 914 also received chemotherapy as part of their regimen. We found that ESR1 mutations had a negative effect on outcome in ET-treated tumors (Figure 2, A and B, both with regard to OS (P = .008, log-rank test) and RFS (P < .001). This association was also seen within the entire ER-positive patient cohort (Supplementary Figure 1, available online). The absolute risk for death in the endocrine-treated patients with ESR1 wild-type was 12.7% (n = 2,456, 312 events) compared with 29.6% (n = 27, 8 events) in the ESR1 mutant group.

Similarly, the absolute risk for an RFS event (death or relapse) was 11.4% (n = 2,364, 269 events) for ESR1 wild-type and 33.3% (n = 27, 9 events) for the mutant group. Four mutation-positive patients suffered a relapse to date; out of these, 2 were positive for D538G, 1 for Y537C, and 1 for Y537N. All 4 received adjuvant treatment with aromatase inhibitors (Supplementary Table 3, available online). To note, for 2 of these patients, we were able to obtain paired tissue samples from the relapse and ascertain ESR1 mutation status in the metastatic site: case S002666 had confirmed Y537C mutation in the lung metastasis at a MAF of 81.9%, and case S005693 had confirmed Y537N mutation in the thoracic wall metastasis at a MAF of 62.5%.

Because of the low total number of mutant cases and outcome events, we performed a series of 2-factor Cox regression multivariable analyses, adjusting in turn for the known prognostic variables: age, tumor size, lymph node status, tumor grade, tumor pathological stage, or HER2 status (Figure 3). The unadjusted hazard ratio for OS was 2.51 (95% confidence interval [CI] = 1.24 to 5.07; P = .01) and ranged between 2.13 when considering age and 2.60 when considering stage, remaining statistically significant across all analyses except when adjusted for lymph node status (Figure 3, A). Similarly, for RFS, ESR1 mutation had an unadjusted hazard ratio of 3.00 (95% CI = 1.56 to 5.88; P = .001), with hazard ratios ranging from 2.75 to 3.74 in the multivariable models, remaining statistically significant in all Cox multivariable models (Figure 3, B).

**Discussion**

To our knowledge, we have conducted the largest study of ESR1 ET resistance mutations in treatment-naive primary breast cancer. Using RNA sequencing of primary breast tumor samples taken at surgery and with a detection limit of minimum 2% MAF, the overall frequency of ESR1 ET resistance mutations in the population-based SCAN-B cohort was 0.9%, corresponding to 1.1% among the ER-positive tumors. When linked to eventual...
## Table 1. Clinical parameters of the patient cohort and for the cases with ESR1 endocrine therapy-resistance mutation

| Clinical parameters         | All cases  | ER-positive group | Endocrine therapy (ET)-treated group | ESR1 mutation-positive cases | \(P\)          |
|----------------------------|------------|-------------------|--------------------------------------|------------------------------|--------------|
|                            | (n = 3217) | (n = 2720)        | (n = 2499)                           | (n = 30)                     |              |
| **Patient age**            |            |                   |                                      |                              |              |
| Median (range), y           | 64 (24-96) | 64 (24-96)        | 64 (24-95)                           | 64.5 (52-85)                 | .046<sup>c</sup> |
| < 50 years old, No. (%)    | 597 (18.6) | 480 (17.6)        | 460 (18.4)                           | 0 (0)                        | .004<sup>d</sup> |
| ≥ 50 years old, No. (%)    | 2620 (81.4)| 2240 (82.4)       | 2039 (81.6)                          | 30 (100.0)                   | .01<sup>d</sup> |
| **Tumor size**             |            |                   |                                      |                              |              |
| Median (range), mm          | 17 (1-126) | 17 (1-126)        | 18 (1-126)                           | 21 (8-50)                    | .14<sup>c</sup> |
| **Lymph node status, No. (%)** |          |                   |                                      |                              |              |
| Node positive               | 1141 (35.5)| 963 (35.4)        | 949 (38.0)                           | 11 (36.7)                    | .70<sup>d</sup> |
| Node negative               | 1913 (59.5)| 1629 (59.9)       | 1430 (57.2)                          | 16 (53.3)                    | .69<sup>d</sup> |
| NA                         | 163 (5.1)  | 128 (4.7)         | 120 (4.8)                            | 3 (10.0)                     |              |
| **Histological grade, No. (%)** |        |                   |                                      |                              |              |
| 1                          | 483 (15)   | 476 (17.5)        | 360 (14.4)                           | 5 (16.7)                     | .75<sup>d</sup> |
| 2                          | 1509 (46.9)| 1452 (53.4)       | 1346 (53.9)                          | 16 (53.3)                    | 1.00<sup>d</sup> |
| 3                          | 1161 (36.1)| 757 (27.8)        | 751 (30.1)                           | 9 (30.0)                     | 1.00<sup>d</sup> |
| NA                         | 64 (2.0)   | 35 (1.3)          | 42 (1.7)                             | 0 (0)                        |              |
| **Estrogen receptor (ER), No. (%)** |       |                   |                                      |                              |              |
| ER positive                 | 2720 (84.6)| 2720 (100)        | 2462 (98.5)                          | 29 (96.7)                    | .11<sup>d</sup> |
| ER negative                 | 463 (14.4) | 0 (0)             | 21 (0.8)                             | 1 (3.3)                      |              |
| NA                         | 34 (1.1)   | 0 (0)             | 16 (0.6)                             | 0 (0)                        |              |
| **Progesterone receptor (PR), No. (%)** |     |                   |                                      |                              |              |
| PR positive                 | 2308 (71.7)| 2287 (84.1)       | 2083 (83.4)                          | 26 (86.7)                    | .14<sup>d</sup> |
| PR negative                 | 824 (25.6) | 375 (13.8)        | 357 (14.3)                           | 4 (13.3)                     | .79<sup>d</sup> |
| NA                         | 85 (2.6)   | 58 (2.1)          | 59 (2.4)                             | 0 (0)                        |              |
| **HER2 receptor, No. (%)**  |            |                   |                                      |                              |              |
| HER2 positive               | 414 (12.9) | 288 (10.6)        | 286 (11.4)                           | 4 (13.3)                     | .79<sup>d</sup> |
| HER2 negative               | 2651 (82.4)| 2312 (85.0)       | 2102 (84.1)                          | 24 (80.0)                    |              |
| NA                         | 152 (4.7)  | 120 (4.4)         | 111 (4.4)                            | 2 (6.7)                      |              |
| **Summary receptor status, No. (%)** |         |                   |                                      |                              |              |
| ER+ or PR+ and HER2+        | 294 (9.1)  | 288 (10.6)        | 279 (11.2)                           | 3 (10.0)                     | .29<sup>d</sup> |
| ER+ or PR+ and HER2-        | 2327 (72.3)| 2312 (85)         | 2092 (83.7)                          | 24 (80.0)                    | 1.00<sup>d</sup> |
| ER-/PR+ and HER2+           | 112 (3.5)  | 0 (0)             | 3 (0.1)                              | 1 (3.3)                      | 1.00<sup>d</sup> |
| ER-/PR- and HER2-           | 310 (9.6)  | 0 (0)             | 5 (0.2)                              | 0 (0)                        |              |
| Ki67, No. (%)               |            |                   |                                      |                              |              |
| Ki67 high                   | 887 (27.6) | 677 (21.0)        | 654 (20.3)                           | 4 (13.3)                     | .33<sup>d</sup> |
| Ki67 low                    | 627 (19.5) | 615 (19.1)        | 513 (15.9)                           | 6 (20.0)                     | .53<sup>d</sup> |
| Ki67 NA                     | 1703 (52.9)| 1428 (44.4)       | 1332 (41.4)                          | 20 (66.7)                    |              |
| **PAM50 subtype, No. (%)**  |            |                   |                                      |                              |              |
| Luminal A                   | 1545 (48.0)| 1519 (55.8)       | 1340 (53.6)                          | 17 (56.7)                    | .23<sup>d</sup> |
| Luminal B                   | 899 (27.9) | 891 (32.8)        | 855 (34.2)                           | 11 (36.7)                    |              |
| HER2 enriched               | 279 (8.7)  | 125 (4.6)         | 132 (5.3)                            | 0 (0)                        |              |
| Basal-like                  | 318 (9.9)  | 34 (1.3)          | 37 (1.5)                             | 1 (3.3)                      |              |
| Normal-like                 | 112 (3.5)  | 90 (3.3)          | 78 (3.1)                             | 0 (0)                        |              |
| Unclassified                | 64 (2.0)   | 61 (2.2)          | 57 (2.3)                             | 1 (3.3)                      |              |
| **Treatment received, No. (%)** |         |                   |                                      |                              |              |
| Endocrine treatment         | 2499 (77.7)| 2462 (90.5)       | 2499 (100)                           | 27 (90.0)                    |              |
| Tamoxifen                   | 1317 (40.9)| 1297 (47.7)       | 1317 (52.7)                          | 12 (40.0)                    |              |
| Aromatase inhibitor         | 1242 (38.6)| 1226 (45.1)       | 1241 (49.7)                          | 15 (50.0)                    |              |
| Chemotherapy                | 1274 (39.6)| 901 (33.1)        | 914 (36.6)                           | 11 (36.7)                    |              |
| HER2 therapy                | 348 (10.8) | 232 (8.5)         | 238 (9.5)                            | 2 (6.7)                      |              |
| Radiotherapy                | 2058 (64.0)| 1747 (64.2)       | 1585 (63.4)                          | 20 (66.7)                    |              |
| **Systemic treatment regimen, No. (%)** |     |                   |                                      |                              |              |
| No systemic treatment       | 336 (10.4) | 233 (8.6)         | 0 (0)                                | 2 (6.7)                      |              |
| Endocrine treatment alone   | 1579 (49.1)| 1571 (57.8)       | 1579 (63.2)                          | 16 (53.3)                    |              |
| Chemotherapy alone          | 252 (7.8)  | 11 (0.4)          | 0 (0)                                | 0 (0)                        |              |

(continued)
therapies administered and patient outcomes, we show for the first time that preexisting ESR1 mutation at diagnosis was statistically significantly associated to poor OS and RFS in the group that received adjuvant endocrine therapy with tamoxifen or aromatase inhibitor. A limitation of this study is the low number of mutant tumors and events, which did not allow for a Cox regression analysis adjusted for all prognostic factors in a single model. Adjustment for all prognostic factors will require a larger collaborative effort. However, in a series of pairwise-adjusted models, we show that resistance mutations at diagnosis of primary breast cancer were associated with a more than 2 times higher risk for death and 3 times higher risk for death or relapse.

There are several limitations to using RNA sequencing for mutation detection. The sequencing coverage of each gene is...
governed by its degree of expression, and therefore, highly transcribed genes will have a higher sequence coverage. Mutations in genes that are not sufficiently expressed or that lead to nonsense-mediated decay of the transcript can be missed, and subclonal mutations at low MAF less than 2% may not be detected. Moreover, RNA editing and artifacts from library preparation and sequencing have the potential to generate false-positive mutation calls. In the case of the ER, this is not a major issue because all mutations of interest are generally well-characterized missense activating mutations, and ESR1 is generally highly expressed in the tumors, where ER is well established to be biologically relevant. It is possible that we may miss ESR1 mutations in ER-negative tumors, although the biological meaning of such variants is unlikely to be pertinent in the adjuvant setting. The successful validation of the variants in tumor DNA for 18 of 18 mutations and not present in 11 of 11 matched germline DNA confirms that our RNA-seq–based approach is specific for detection of true-positive somatic ESR1 mutations.

The Y537S, Y537N, Y537C, and D538G variants were found in 13 samples in our cohort. These altered ER proteins have previously been well characterized and shown to be powerful activators of downstream ER signaling. The most commonly occurring resistance mutation in our study, E380Q, is also the most common variant in primary breast tumors within The Cancer Genome Atlas (TCGA) (21). E380Q has been described as a gain-of-function variant that confers a growth advantage to cells in the absence of estrogen as well as relative resistance to tamoxifen and fulvestrant (6), although it may have a less potent effect on estrogen receptor activity in vitro compared with other mutations (8). E380Q has also been detected in other studies of treatment-resistant breast tumors (22-24), but its effects in vivo are not well understood. Of note, none of the E380Q-positive cases in our cohort suffered a relapse, and only 1 case had a death event.

Interestingly, all ESR1 mutants occurred in patients who were diagnosed at age 50 years or older. Of these, patient surveys indicated that 96.7% were postmenopausal. The origin of preexisting ESR1 mutation is unclear. One hypothesis is that they arise through age-related stochastic mutational events. Another hypothesis is that hormone replacement therapy could supply estrogenic signaling that may select for ESR1-mutant premalignant clones. Unfortunately, in this study, no data on hormone replacement therapy were available. These hypotheses should be investigated in future studies.

The presence of ET resistance mutations has been demonstrated to adversely affect OS by a median of almost 12 months in metastatic breast cancer (11). Here, we demonstrate for the first time that ESR1 mutation is detrimental in primary breast cancer, showing that ESR1 ET resistance mutations that preexist any systemic therapy are associated to poor OS and RFS in patients who receive adjuvant ET. These results contribute additional evidence that ER mutations impact the response to endocrine therapy. Mutant ER receptors can have diverse drug sensitivity profiles, and therefore, it is of great importance to enable detection and genotyping of these variants to aid clinicians in the decision process for choice of treatments. Presence of even a small population of ET-resistant cells could result in treatment failure and recurrence, and high-sensitivity screening using tissue and liquid biopsy plasma-circulating tumor DNA tests such as IBSAFE may be informative, not only for prognosis prediction but also for helping inform clinical decisions on which hormonal treatment options may most effectively reduce the risk of relapse for individual patients.

In conclusion, our results suggest that preexisting ESR1 ET resistance mutations in untreated primary breast cancer are rare but are associated to poor outcome and resistance to standard hormone therapy. If our results are replicated, ESR1 screening should be considered in ER-positive primary breast cancer, and for patients with mutated disease, ER degraders such as fulvestrant or other agents in development may be more appropriate.

**Funding**

This work was supported by the Mrs Berta Kamprad Foundation and was also funded in part by the Swedish Foundation for Strategic Research; Swedish Research Council; Swedish Cancer Society; Knut and Alice Wallenberg Foundation; VINNOVA; Governmental Funding of Clinical
A Cox Regression: OS in endocrine-treated patients

| Multivariable models | Clinical variable | Total / events | Hazard Ratio | HR (95% CI) | P value |
|----------------------|------------------|----------------|--------------|--------------|---------|
| ESR1 only            | ESR1 WT          | 2456 / 312     |              | reference    |         |
|                      | ESR1 mutation    | 27 / 8         | 2.51 (1.24 to 5.07) | .01         |
| ESR1 and Age         | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1450 / 275     | 2.13 (1.08 to 4.30) | .03         |
|                      | Age: < 50 years  | 454 / 15       | reference    |              |         |
|                      | Age: ≥ 50 years  | 2029 / 305     | 4.70 (2.80 to 7.90) | < .001      |
| ESR1 and Tumor Size  | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1440 / 125     | 2.32 (1.15 to 4.68) | .02         |
|                      | Tumor Size: < 20 mm | 454 / 15 | reference    |              |         |
|                      | Tumor Size: ≥ 20 mm | 1028 / 193 | 2.28 (1.82 to 2.85) | < .001      |
| ESR1 and Node status | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1420 / 162     | 2.08 (0.93 to 4.68) | .08         |
|                      | Node negative    | 944 / 131      | 1.26 (1.00 to 1.58) | .05         |
|                      | Node positive    | reference      |              |              |         |
| ESR1 and NHG         | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 357 / 29       | 2.55 (1.27 to 5.15) | .009        |
|                      | Grade 1          | 1338 / 163     | 1.57 (1.06 to 2.34) | .02         |
|                      | Grade 2          | 747 / 124      | 2.21 (1.48 to 3.32) | < .001      |
|                      | Grade 3          | 442 / 28       | reference    |              |         |
| ESR1 and Stage       | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1202 / 102     | 2.60 (1.23 to 5.51) | .01         |
|                      | Stage 1          | 902 / 160      | 2.10 (1.65 to 2.86) | < .001      |
|                      | Stage 2          | 483 / 22       | 6.53 (4.12 to 10.36) | < .001      |
|                      | Stage 3          | 1949 / 250     | 2.00 (1.33 to 2.91) | < .001      |
| ESR1 and HER2        | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 2091 / 279     | 3.03 (1.62 to 5.68) | .001        |
|                      | HER2 negative    | 283 / 37       | 1.00 (0.71 to 1.41) | .99         |
|                      | HER2 positive    | reference      |              |              |         |

B Cox Regression: RFS in endocrine-treated patients

| Multivariable models | Clinical variable | Total / events | Hazard Ratio | HR (95% CI) | P value |
|----------------------|------------------|----------------|--------------|--------------|---------|
| ESR1 only            | ESR1 WT          | 2364 / 276     |              | reference    |         |
|                      | ESR1 mutation    | 27 / 9         | 3.00 (1.56 to 5.88) | .001        |
| ESR1 and Age         | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1386 / 111     | 2.94 (1.51 to 5.73) | .001        |
|                      | Grade 1          | 342 / 22       | 2.00 (1.33 to 2.91) | < .001      |
|                      | Grade 2          | 1294 / 143     | 2.10 (1.65 to 2.86) | < .001      |
|                      | Grade 3          | 1949 / 250     | 2.00 (1.33 to 2.91) | < .001      |
| ESR1 and Tumor Size  | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1386 / 111     | 2.94 (1.51 to 5.73) | .001        |
|                      | Tumor Size: < 20 mm | 981 / 167 | reference    |              |         |
|                      | Tumor Size: ≥ 20 mm | 1028 / 193 | 2.10 (1.65 to 2.86) | < .001      |
| ESR1 and Node status | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 1372 / 142     | 3.05 (1.51 to 6.18) | .002        |
|                      | Node negative    | 910 / 113      | 1.26 (0.98 to 1.61) | .07         |
|                      | Node positive    | reference      |              |              |         |
| ESR1 and NHG         | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 342 / 22       | 3.15 (1.62 to 6.14) | < .001      |
|                      | Grade 1          | 1294 / 143     | 1.77 (1.13 to 2.78) | .01         |
|                      | Grade 2          | 715 / 110      | 2.43 (1.54 to 3.84) | < .001      |
|                      | Grade 3          | 1162 / 93      | 3.28 (1.62 to 6.65) | < .001      |
| ESR1 and Stage       | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 876 / 134      | 1.88 (1.44 to 2.45) | < .001      |
|                      | Stage 1          | 45 / 18        | 4.50 (2.71 to 7.45) | < .001      |
|                      | Stage 2          | 1949 / 250     | 2.00 (1.33 to 2.91) | < .001      |
|                      | Stage 3          | 2013 / 236     | 3.74 (1.37 to 10.19) | .01         |
| ESR1 and HER2        | ESR1 WT          | reference      | reference    |              |         |
|                      | ESR1 mutation    | 274 / 37       | 1.72 (1.03 to 2.87) | .04         |

Figure 3. Cox regression models for ESR1 mutation at diagnosis in early breast cancer. Forest plots for overall survival (A) and relapse-free survival (B) in the endocrine-treated group. HR = hazard ratio; OS = overall survival; RFS = relapse-free survival; WT = wild-type; NHG = Nottingham histological grade.
Research within National Health Service; Lund University Medical Faculty; Gunnar Nilsson Cancer Foundation; Skåne University Hospital Foundation; BioCARE Research Program; King Gustav Vth Jubilee Foundation; Kräpperup Foundation; Lund-Lausanne L2-Bridge/Biltema Foundation; and the Mats Paulsson Foundation.

Notes

Role of the funders: The funders had no role in study design, collection, analysis, and interpretation of the data.

Disclosures: AMG, CB, YC, SG, and LHS have ownership interest (including stock, patents, etc.) in SAGA Diagnostics. LHS has received honoraria from Novartis and Boehringer-Ingelheim. The authors have declared no other potential conflicts of interest.

Author contributions: MD, SKG-S, and LHS conceived the study. MD, AMG, CB, SG, YC, JV-C, JH, NL, and LHS analyzed data. JV-C, CH, JH, LR, MM, CL, AE, NL, ÅB, and LHS established the SCAN-B Initiative. CB, SG, and LHS established the RNA-seq mutation calling pipeline and filters. JV-C, CH, JH, LR, MM, CL, AE, NL, ÅB, and LHS provided clinical information. LHS supervised the project, and MD and LHS wrote the report with assistance from all authors. All authors discussed, critically revised, and approved the final version of the report for publication.

Acknowledgements: The authors thank the patients, clinicians, and hospital staff participating in the SCAN-B study, the staff at the central SCAN-B laboratory at Lund University, the Swedish National Breast Cancer Quality Registry (NKBC), Regional Cancer Center South, the South Swedish Breast Cancer Group (SSBCG), and the members of the Translational Oncogenomics Unit, Division of Oncology, Lund University.

Prior presentations: The work herein was presented orally at the American Association for Cancer Research (AACR) Annual Meeting in April 2020.

Data Availability

The RNA-sequencing data is publicly available from the NCBI Gene Expression Omnibus database, accession GSE81540 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81540).

References

1. Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4(6):1116–1130.
2. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446–1451.
3. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439–1445.
4. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. J Clin Oncol. 2014;32(7):1757–1767.
5. Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125(21):3714–3728. doi:10.1002/cncr.32345.
6. Kuang Y, Siddiqui B, Hu J, et al. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018;4:22.
7. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2015;75(19):5242–5255.
8. Toy W, Weir H, Razavi P, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7(3):277–287.
9. Bahreini A, Li Z, Wang P, et al. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Res. 2017;19(1):60.
10. Jeselsohn R, Bergholz JS, Pun M, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell. 2018;33(2):173–186.
11. Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLEGO-2 clinical trial. JAMA Oncol. 2016;2(10):1310–1315.
12. Wang F, Balsinetti A, Gyanchandani R, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res. 2016;22(9):1130–1137.
13. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget. 2017;8(32):52422–52433.
14. Fumagalli D, Wilson TR, Salgado R, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Ann Oncol. 2016;27(10):1860–1866.
15. Saal LH, Vallen-Christersson J, Hakkinen J, et al. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.
16. Jensen L, Loman N, Larsson C, et al. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br J Surg. 2018;105(2):e158–e168.
17. Brueffer C, Vallen-Christersson J, Grabau D, et al. Clinical value of RNA sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. J Clin Oncol Precis Oncol. 2018;2:1–18.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–410.
19. Brueffer C, Glauchak S, Winter C, et al. The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome. EMBO Mol Med. 2020;12(10):e12118. doi:10.15252/emmm.202012118.
20. Forvik D, Aaltaen KE, Chen Y, et al. Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment. Breast Cancer Res Treat. 2019;177(2):447–455. doi:10.1007/s10549-019-05256-5.
21. Liu J, Lichtenberg T, Headley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality outcome analytics. Cell. 2018;173(2):400–416. e11.
22. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. BMC Cancer. 2017;17(1):786.
23. Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the therapeutic vulnerabilities of ESR1 activating mutations. Cancer Res. 2015;75(20):5242–5252.
24. Shaw JA, Gutierrez DS, Hills A et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23(3):88–96.